CCL2 and CXCL10 production

CCL2 and CXCL10 production refers to the biological process of synthesizing and secreting two critical pro-inflammatory chemokines: C-C Motif Chemokine Ligand 2 (CCL2), also known as Monocyte Chemoattractant Protein-1 (MCP-1), and C-X-C Motif Chemokine Ligand 10 (CXCL10), also known as Interferon gamma-induced protein 10 (IP-10) (UniProt P13500, P02778). CCL2 is primarily responsible for the recruitment of monocytes, memory T cells, and dendritic cells to sites of inflammation, while CXCL10 recruits activated T cells and natural killer cells (PubMed 29026324). This process is not a single therapeutic target but rather a downstream readout of various signaling pathways, including the JAK/STAT and NF-kappaB pathways, which are often activated by pro-inflammatory cytokines like Interferon-gamma and TNF-alpha (PubMed 32653375). Dysregulation of CCL2 and CXCL10 production is implicated in a wide range of diseases, including rheumatoid arthritis, cardiovascular disease, and viral infections like COVID-19 (PubMed 32835032). Pharmacological intervention typically involves using inhibitors of upstream kinases, such as JAK inhibitors (e.g., Baricitinib), or transcription factors to dampen the inflammatory response (PubMed 32653375).

Other names

MCP-1 and IP-10 productionChemokine productionMonocyte chemoattractant protein-1 and Interferon gamma-induced protein 10 production

Inhibition of upstream signaling pathways such as JAK/STAT, NF-kappaB, or MAPK to reduce the expression and secretion of these chemokines.